MCLA-129
mAbexperimentalBi-specific
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 28, 2021 (NCT04868877)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1/Phase 2
- Lung Neoplasms · Phase 1
- Neoplasms · Phase 1/Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 1/Phase 2
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06885840 | Phase 2 | Mar 31, 2025 | Betta Pharmaceuticals Co.,Ltd. |
| NCT06015568 | Phase 1 | Sep 1, 2023 | Betta Pharmaceuticals Co.,Ltd., Jiao Tong University |
| NCT04930432 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2021 | Betta Pharmaceuticals Co.,Ltd., Chinese Academy of Medical Sciences |
| NCT04868877 | Phase 1/Phase 2 (Phase 2) | Apr 28, 2021 | Merus Labs |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Betta Pharmaceuticals Co.,Ltd. | For profit | 3 | 3 | 2 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Merus Labs | For profit | 1 | 1 | 1 | 2021 |
4 organizations
Page 1 / 1